Business Context and Reporting Period
This Form 8-K reports on the 2014 Annual Meeting of Stockholders for Alnylam Pharmaceuticals, Inc., held on September 25, 2014. The record date for the meeting was August 15, 2014, with 76,365,403 shares issued and outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Elections: Stockholders re-elected three Class I directors to serve until the 2017 annual meeting.
- John M. Maraganore, Ph.D.: 62,826,534 votes for; 998,712 withheld.
- Paul R. Schimmel, Ph.D.: 63,076,873 votes for; 748,373 withheld.
- Phillip A. Sharp, Ph.D.: 62,376,504 votes for; 1,448,742 withheld.
The terms of six other directors (Dennis A. Ausiello, John K. Clarke, Marsha H. Fanucci, Steven M. Paul, Amy W. Schulman, and Kevin P. Starr) continued after the meeting.
- Executive Compensation: Stockholders approved the compensation of named executive officers in a non-binding advisory vote.
- Votes For: 62,382,890
- Votes Against: 1,345,787
- Abstentions: 96,569
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2014.
- Votes For: 68,939,036
- Votes Against: 136,388
- Abstentions: 51,580
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors to Verify
- Confirmation that the three Class I directors were successfully re-elected with significant majority support.
- Verification of the non-binding advisory vote results regarding executive compensation, noting approximately 2.1% of votes cast were against.
- Confirmation that PricewaterhouseCoopers LLP was ratified as the independent auditor for the 2014 fiscal year.
- Review of the total broker non-votes (5,301,758) which impacted the voting totals for director elections and executive compensation.